Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04806620 · ClinicalTrials.gov registry record
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
A clinical trial of Celiac Disease and Post-Acute COVID-19 Syndrome, sponsored by Brain Inflammation Collaborative.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT04806620 is a study of Celiac Disease and Post-Acute COVID-19 Syndrome that is actively recruiting participants, run by Brain Inflammation Collaborative. The registered enrollment target is 10,000 participants, above the 1,563-participant average among 24 other Celiac Disease trials with a reported enrollment target (540% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04806620, a study of Celiac Disease and Post-Acute COVID-19 Syndrome, is actively recruiting participants, sponsored by Brain Inflammation Collaborative.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. "Healthy" individuals without brain inflammation are also eligible to participate. The digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.
Conditions Studied
Study Locations (1)
Wisconsin
- Brain Inflammation Collaborative - Delafield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2023-07-05 |
| Est. Completion | 2030-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04806620
The ClinicalTrials.gov registry entry for NCT04806620 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,563-participant average among 24 other Celiac Disease trials with a reported enrollment target (540% higher). The listed sponsor is Brain Inflammation Collaborative, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Celiac Disease appearing as the primary indexed condition, and to 0 interventions.
NCT04806620 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04806620 about?
NCT04806620 is a clinical study titled "Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research". The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years ...
What is the current status of trial NCT04806620?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2023-07-05. Estimated completion is 2030-12-31.
What conditions does trial NCT04806620 study?
This clinical trial studies the following conditions: Celiac Disease, Post-Acute COVID-19 Syndrome, ME/CFS, Chronic Lyme Disease, Celiac Disease in Children.
Who is sponsoring clinical trial NCT04806620?
This trial is sponsored by Brain Inflammation Collaborative, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04806620 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
-
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
RECRUITING
-
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
RECRUITING · Phase 1
-
Immune Responses to Gluten
RECRUITING · NA
-
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
RECRUITING · Phase 2
-
Urine Metabolites in the Diagnosis of Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.